: Cancer therapy has advanced with molecularly targeted approaches and immunotherapy, yet chemotherapy remains essential for many aggressive cancers, including breast, lung, ovarian, pancreatic, bladder, sarcoma, and lymphomas. A major challenge is chemoresistance, in which cancer cells evade chemotherapy's cytotoxic effects. Overexpression of adenosine triphosphate-binding cassette transporters, especially P-glycoprotein, significantly contributes to this resistance. Thus, imaging biomarkers are urgently needed to detect P-glycoprotein overexpression in vivo, identify resistant cancer cell clones, and map their distribution and heterogeneity within tumors. This article reviews the applications of SPECT, PET, and optical imaging in addressing chemoresistance. It emphasizes the potential of these modalities to enhance cancer treatment by enabling early identification of resistant clones and improving therapeutic strategies. The article outlines key steps required for the integration of molecular imaging into clinical practice, aiming to overcome chemoresistance and optimize patient outcomes.

Urso, L., Uccelli, L., Boschi, A., Schillaci, O., Filippi, L. (2025). Molecular Imaging in Cancer Chemoresistance: What's Brewing?. THE JOURNAL OF NUCLEAR MEDICINE [10.2967/jnumed.124.268967].

Molecular Imaging in Cancer Chemoresistance: What's Brewing?

Schillaci, Orazio;Filippi, Luca
2025-02-06

Abstract

: Cancer therapy has advanced with molecularly targeted approaches and immunotherapy, yet chemotherapy remains essential for many aggressive cancers, including breast, lung, ovarian, pancreatic, bladder, sarcoma, and lymphomas. A major challenge is chemoresistance, in which cancer cells evade chemotherapy's cytotoxic effects. Overexpression of adenosine triphosphate-binding cassette transporters, especially P-glycoprotein, significantly contributes to this resistance. Thus, imaging biomarkers are urgently needed to detect P-glycoprotein overexpression in vivo, identify resistant cancer cell clones, and map their distribution and heterogeneity within tumors. This article reviews the applications of SPECT, PET, and optical imaging in addressing chemoresistance. It emphasizes the potential of these modalities to enhance cancer treatment by enabling early identification of resistant clones and improving therapeutic strategies. The article outlines key steps required for the integration of molecular imaging into clinical practice, aiming to overcome chemoresistance and optimize patient outcomes.
6-feb-2025
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MEDS-22/A - Diagnostica per immagini e radioterapia
English
P-glycoprotein; radiochemistry; molecular imaging
PET
cancer
chemotherapy
Urso, L., Uccelli, L., Boschi, A., Schillaci, O., Filippi, L. (2025). Molecular Imaging in Cancer Chemoresistance: What's Brewing?. THE JOURNAL OF NUCLEAR MEDICINE [10.2967/jnumed.124.268967].
Urso, L; Uccelli, L; Boschi, A; Schillaci, O; Filippi, L
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Pubblicazione n. 13.pdf

solo utenti autorizzati

Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 12.6 MB
Formato Adobe PDF
12.6 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/413584
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact